Preventing Tumor Progression in Women with High-Risk DCIS

Rationale: We reason that a TSEC agent that reverts pro-tumorigenic effects in fibroblasts in vitro may prove beneficial in women newly diagnosed with DCIS, thus offering novel therapeutic opportunities. Experimental design: We will provide five slides from the pre- and post-intervention biopsies in 20 patients from a pilot trial aimed at evaluating the benefit of a TSEC agent (Duavee) in a prospective randomized cohort of women diagnosed with DCIS and treated with the TSEC or Placebo for 28+/-7 days between their initial diagnosis of DCIS and their surgical resection. The combined information gained from the trial and the proposed study will provide invaluable insights into the therapeutic potential of TSEC in women diagnosed with DCIS.